UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2017
TRACON Pharmaceuticals, Inc. |
(Exact name of registrant as specified in its charter) |
|
Delaware | | 001-36818 | | 34-2037594 |
(State or other jurisdiction | | (Commission File Number) | | (IRS Employer Identification No.) |
of incorporation) | | | | |
| | | | |
| | | | |
| | | | |
4350 La Jolla Village Drive, Suite 800 San Diego, California | | 92122 |
(Address of principal executive offices) | | (Zip Code) |
| | | | |
| Registrant’s telephone number, including area code: (858) 550-0780 | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On July 25, 2017, TRACON Pharmaceuticals, Inc. (“TRACON”) issued a press release announcing that Santen Pharmaceutical Co. Ltd. (“Santen”) has initiated a Phase 2a clinical study of DE-122 in patients with wet age-related macular degeneration (AMD). DE-122 is the ophthalmic formulation of TRACON’s proprietary anti-endoglin antibody, TRC105. The initiation of the Phase 2a study triggers Santen’s obligation to make a US$7.0 million milestone payment to TRACON under the terms of the companies’ license agreement related to DE-122.
A copy of this press release is attached as Exhibit 99.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
| | |
99.1 | | Press release issued by TRACON Pharmaceuticals, Inc. dated July 25, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRACON Pharmaceuticals, Inc. |
Dated: July 26, 2017 | By: | /s/ Charles P. Theuer, M.D., Ph.D. | |
| | Charles P. Theuer, M.D., Ph.D. President and Chief Executive Officer |
| | |
EXHIBIT INDEX
| | |
| | |
Exhibit No. | | Description |
99.1 | | Press release issued by TRACON Pharmaceuticals, Inc. dated July 25, 2017. |
